VIVO BIO TECH | SYNGENE INTERNATIONAL | VIVO BIO TECH/ SYNGENE INTERNATIONAL |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 37.3 | 60.9 | 61.2% | View Chart |
P/BV | x | 1.2 | 7.4 | 15.6% | View Chart |
Dividend Yield | % | 0.0 | 0.2 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VIVO BIO TECH Mar-21 |
SYNGENE INTERNATIONAL Mar-22 |
VIVO BIO TECH/ SYNGENE INTERNATIONAL |
5-Yr Chart Click to enlarge
|
||
High | Rs | 71 | 700 | 10.2% | |
Low | Rs | 18 | 508 | 3.5% | |
Sales per share (Unadj.) | Rs | 38.6 | 65.0 | 59.4% | |
Earnings per share (Unadj.) | Rs | 4.2 | 9.9 | 42.9% | |
Cash flow per share (Unadj.) | Rs | 8.4 | 17.6 | 47.7% | |
Dividends per share (Unadj.) | Rs | 0 | 1.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.2 | 0.0% | |
Book value per share (Unadj.) | Rs | 30.6 | 80.1 | 38.2% | |
Shares outstanding (eoy) | m | 13.42 | 400.80 | 3.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.2 | 9.3 | 12.4% | |
Avg P/E ratio | x | 10.5 | 61.2 | 17.2% | |
P/CF ratio (eoy) | x | 5.3 | 34.3 | 15.4% | |
Price / Book Value ratio | x | 1.5 | 7.5 | 19.3% | |
Dividend payout | % | 0 | 10.1 | 0.0% | |
Avg Mkt Cap | Rs m | 597 | 242,091 | 0.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 86 | 7,181 | 1.2% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 518 | 26,042 | 2.0% | |
Other income | Rs m | 1 | 1,084 | 0.1% | |
Total revenues | Rs m | 519 | 27,126 | 1.9% | |
Gross profit | Rs m | 178 | 7,098 | 2.5% | |
Depreciation | Rs m | 56 | 3,097 | 1.8% | |
Interest | Rs m | 37 | 241 | 15.2% | |
Profit before tax | Rs m | 86 | 4,844 | 1.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 29 | 886 | 3.3% | |
Profit after tax | Rs m | 57 | 3,958 | 1.4% | |
Gross profit margin | % | 34.3 | 27.3 | 126.0% | |
Effective tax rate | % | 34.1 | 18.3 | 186.3% | |
Net profit margin | % | 11.0 | 15.2 | 72.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 271 | 22,059 | 1.2% | |
Current liabilities | Rs m | 218 | 12,289 | 1.8% | |
Net working cap to sales | % | 10.1 | 37.5 | 27.0% | |
Current ratio | x | 1.2 | 1.8 | 69.1% | |
Inventory Days | Days | 0 | 190 | 0.0% | |
Debtors Days | Days | 51,413,598 | 71 | 72,252,404.8% | |
Net fixed assets | Rs m | 524 | 32,923 | 1.6% | |
Share capital | Rs m | 134 | 4,008 | 3.3% | |
"Free" reserves | Rs m | 277 | 28,093 | 1.0% | |
Net worth | Rs m | 411 | 32,101 | 1.3% | |
Long term debt | Rs m | 147 | 5,315 | 2.8% | |
Total assets | Rs m | 795 | 54,982 | 1.4% | |
Interest coverage | x | 3.3 | 21.1 | 15.9% | |
Debt to equity ratio | x | 0.4 | 0.2 | 215.3% | |
Sales to assets ratio | x | 0.7 | 0.5 | 137.5% | |
Return on assets | % | 11.8 | 7.6 | 154.1% | |
Return on equity | % | 13.8 | 12.3 | 112.1% | |
Return on capital | % | 22.1 | 13.6 | 162.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 26.8 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 6,967 | 0.0% | |
Fx inflow | Rs m | 19 | 23,253 | 0.1% | |
Fx outflow | Rs m | 42 | 6,967 | 0.6% | |
Net fx | Rs m | -23 | 16,286 | -0.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 142 | 5,806 | 2.4% | |
From Investments | Rs m | -228 | -6,115 | 3.7% | |
From Financial Activity | Rs m | 88 | -313 | -28.1% | |
Net Cashflow | Rs m | 1 | -615 | -0.2% |
Indian Promoters | % | 42.2 | 70.3 | 60.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 18.3 | - | |
FIIs | % | 0.0 | 14.1 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 57.8 | 29.7 | 194.7% | |
Shareholders | 12,632 | 128,278 | 9.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare VIVO BIO TECH With: VA TECH WABAG DELTA CORP HEALTHCARE GLOBAL ENTER. YAARII DIGITAL INTEGRATED SANGHVI MOVERS
Asian share markets opened higher today as another round of weak US data provided a little hope that the Federal Reserve will temper its pace of interest rate hikes.